Lilly expects Zepbound approval in Japan by mid-2025: report
by
Contributor since / Followers
Contributor since / Followers
1 month ago
JHVEPhoto
- Eli Lilly (NYSE:LLY) is reportedly expecting Japanese regulators to approve its weight-loss drug Zepbound for that market by the middle of 2025.
- Lilly CEO David Ricks said in an interview with Nikkei Asia that the company’s application in Japan was on track and that it expects to receive approval by the middle of next year.
- Zepbound competes in the global weight-loss market with Novo Nordisk’s (NVO) Wegovy. Japanese regulators approved Wegovy last year.